Cigna Is Getting A Bargain

Summary

Express Scripts has 6-7% upside before the proxy vote on August 24th.

I estimate odds of a 'yes' vote are at least 5-1.

Carl Icahn was wrong, Express Scripts is worth at least $67 billion to Cigna.

Express Scripts EV/EBIT is at a 25 year low.

The proxy vote on August 24th where shareholders will determine if Cigna (NYSE:CI) will purchase Express Scripts (ESRX) is only a few days away. The market believes with a small dash of doubt that shareholders will vote 'yes' as evidenced by Express Scripts advancing nearly 20% over the past two weeks from $76 into the mid-high 80s. Yet Express' share price hasn't quite reached Cigna's 'offering price' of around $94. Cigna is offering $48.75 cash and 0.2434 Cigna shares per Express share. With Express' share price at $88 and Cigna's at $186, Express is trading at a 6.4% discount to the 'offering price'. The discount reflects the uncertainty the market has in the 'yes' vote. Buying Express Scripts before the vote could net a quick gain in the event of a 'yes' vote, but the downside is large in the event shareholders vote 'no'. In the event of a 'no' vote, Express' share price could very well drop into the high 60s where it sat for most of 2017 and will likely rebound to $70-80 range where it traded before the announcement. The trade off of capturing a 6-7% gain with the risk of losing 20% or more is not for those who lack conviction. The payoff based off of the two companies share prices barring other factors leads me to believe the odds of shareholders approving the buyout is at least 3-1.

READ FULL ARTICLE HERE